Oscar Health, Inc. (OSCR) shares soared 5.29% in pre-market trading on Tuesday, despite reporting disappointing second-quarter results for 2025. The health insurance technology company's stock rally appears to be driven by its revised and potentially optimistic outlook for the full year 2025.
According to the company's preliminary financial results, Oscar Health reported a Q2 adjusted EBITDA of -$120 million, falling short of the IBES estimate of $116.9 million. The net income for the quarter stood at a substantial loss of $228 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking projections.
Oscar Health revised its 2025 guidance, now anticipating annual revenue between $12.0 billion and $12.2 billion. Additionally, the company expects a Medical Loss Ratio of 86.0% to 87.0% for 2025. These projections appear to have instilled confidence in investors, potentially indicating improved operational efficiency and growth prospects for the company. The market's positive reaction suggests that these forward-looking metrics may have exceeded previous expectations, overshadowing the current quarter's weak performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。